Signant SmartSignals Unifed Platform Serves As An eSource For A COVID Treatment Trial

An emerging biopharmaceutical company utilized multiple solutions with Signant SmartSignals Unified Platform to conduct a phase II trial of a COVID treatment in critically ill patients, optimizing technology to meet the unique challenges of the trial and population.

See how the fully integrated platform was implemented two weeks faster than the proposed timeline, while taking into account all the study needs, including eSource data capture.